Groupes de recherche

The Bommer Lab's aim is to reveal novel metabolic mechanisms underlying the development of human diseases ranging from cancer to neurodegeneration.

The Collet Lab studies how bacteria deal with stress, including antibiotics.

The Constantinescu Lab studies how blood is formed under the influence of small proteins called cytokines and how blood cancers can be targeted.

The Coulie Lab studies how immunity contributes to the efficacy of a standard treatment againt bladder cancer.

The Coutelier Lab studies how infectious agents interact with their host immune microenvironment, especially in the context of South countries.

The De Smet Lab studies the causes and consequences of epigenetic alterations in cancer.

The Decottignies Lab studies telomere regulation in the context of cancer and aging

The Demoulin Lab studies the roles of PDGF receptors in human diseases, with a focus on pediatric tumors and leukemia.

The Dewachter Lab studies how the bacterium Streptococcus pneumoniae regulates its cell cycle to better understand its requirements for growth

The Dumoutier Lab studies how cytokines regulate mucosal inflammatory diseases.

The Gatto Lab developes and applies statistical learning methods and implements dedicated software to analyse and comprehend high dimensional biological data.

The Henriet Lab studies how incorrect response to estrogens and progestogens contributes to pathogenesis of endometrial diseases.

The Jacquemin Lab studies the molecular and cellular mechanisms involved in the development of pancreatic diseases, in particular cancer.

The Laloux lab explores the molecular mechanisms and cellular organization underlying the non-canonical lifestyle of predatory bacteria.

The Lemaigre Lab studies how genes control embryonic development of the liver, and how dysfunction of these genes induces tumour formation in adults.

The Lien lab studies how signaling molecules regulate the behavior of skin stem cells in health and disease

The Limaye Lab studies factors that regulate the human immune system, rendering it too permissive (in cancer) or overactive (in autoimmune and autoinflammatory disorders).

The Lucas Lab studies how Tregs and TGF-β suppress immune responses in patients with cancer or auto-immune diseases.

The Michiels Lab studies how viral proteins interfere with host cell biology and with innate immune responses.

The Pierreux Lab studies how epithelial cells organize and communicate with the microenvironment in epithelial diseases.

The Rider Lab studies how the AMP-activated protein kinase (AMPK) and insulin/protein kinase B (PKB) signalling pathways control cell function.

The Staerk Lab studies induced pluripotent cells, hematopoietic stem cell generation and differentiation mechanisms of blood progenitor cells.

The Stockis Lab studies how tissue-resident immune cells control disease pathogenesis, from allergy and inflammation to cancer.

The Tyteca Lab studies how plasma membrane lipid distribution and biophysical properties control cell deformation in physiology and pathology.

The Van den Eynde Lab aims to improve cancer immunotherapy by leveraging new cancer vaccine approaches and understanding immunosuppressive mechanisms in the tumor microenvironment.

The van der Bruggen Lab tries to understand why tumor-infiltrating lymphocytes fail to destroy tumor cells in order to identify new therapeutic targets.

The van Gastel Lab studies how metabolites control the behavior of normal and malignant stem cells.

Emile Van Schaftingen collaborates with other groups (Maria Veiga da Cunha, Guido Bommer) in the institute to elucidate new inborn errors of metabolism.

The Veiga-da-Cunha Lab focuses on understanding the impact of specific enzyme deficiencies on intermediary metabolism to find novel treatments.

The Vigneron lab studies the processing of peptides recognized by cytolytic T lymphocytes on tumors, with a view to improve cancer immunotherapy. 

The Vikkula Lab studies the genetic variations underlying human diseases.

The Zhu lab focuses on pioneering advancements in tumor immunotherapy, including novel targets, improved delivery methods, and uncovering resistance mechanisms.